SCHEMBL6316293

SCHEMBL6316293

NC(=O)c1c(-c2ccccn2)noc1NS(=O)(=O)c1cc(Cl)sc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.41
ACLY P53396 1/20 0.41
EDNRA P25101 4/20 0.40
RET P07949 1/20 0.39
PFKFB3 Q16875 1/20 0.39
CDK1 P06493 1/20 0.38
CCNB1 P14635 1/20 0.38
CCNA2 P20248 1/20 0.38
CCND1 P24385 1/20 0.38
CDK2 P24941 1/20 0.38
CDK7 P50613 1/20 0.38
CCNH P51946 1/20 0.38
CCNA1 P78396 1/20 0.38
CDK6 Q00534 1/20 0.38
EDNRB P24530 1/20 0.38
CYP2C9 P11712 1/20 0.37
PIK3C3 Q8NEB9 1/20 0.37
SGK1 O00141 3/20 0.36
S100A9 P06702 3/20 0.36
TYMS P04818 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6323646 0.87 EDNRA (0.44) TDP1ACLYEDNRAPFKFB3CDK1
SCHEMBL6317676 0.80 EDNRA (0.46) EDNRAEDNRB
SCHEMBL6318219 0.79 EDNRA (0.42) EDNRARETEDNRB
SCHEMBL6315903 0.78 KDM4E (0.50) TDP1EDNRARET
SCHEMBL6323782 0.76 EDNRA (0.48) TDP1EDNRAEDNRBCYP2C9
SCHEMBL6315510 0.76 MEN1 (0.40) EDNRARETEDNRB
SCHEMBL6315506 0.74 GLO1 (0.40) EDNRARET
SCHEMBL6316055 0.73 KDM4E (0.56) TDP1
SCHEMBL6317766 0.73 EDNRA (0.38) EDNRARETEDNRB
SCHEMBL6324589 0.71 EDNRA (0.48) EDNRAEDNRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 TDP1 527/4885ACLY 2690/4885EDNRA 4545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.